OptimizeRx (NASDAQ:OPRX) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of OptimizeRx (NASDAQ:OPRX) from a strong-buy rating to a buy rating in a report issued on Monday morning.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings downgraded OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Stephens decreased their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, May 13th. Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Lake Street Capital dropped their target price on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, B. Riley Financial cut their target price on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.43.

OptimizeRx Stock Down 2.7%

Shares of NASDAQ OPRX opened at $6.51 on Monday. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $22.25. The firm has a market capitalization of $122.13 million, a price-to-earnings ratio of 18.60 and a beta of 1.08. The stock has a 50 day moving average price of $5.47 and a 200 day moving average price of $7.47. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The company had revenue of $19.84 million for the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. Sell-side analysts expect that OptimizeRx will post 0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx during the 2nd quarter worth $44,000. BNP Paribas Financial Markets grew its stake in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue bought a new position in OptimizeRx in the fourth quarter worth about $62,000. Aaron Wealth Advisors LLC bought a new position in OptimizeRx in the first quarter worth about $66,000. Finally, Worth Venture Partners LLC purchased a new stake in shares of OptimizeRx during the third quarter valued at about $220,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.